Touro Scholar
NYMC Faculty Publications

Faculty

3-1-2016

Impact of Spironolactone on Longitudinal Changes in HealthRelated Quality of Life in the Treatment of Preserved Cardiac
Function Heart Failure With an Aldosterone Antagonist Trial
Eldrin Lewis
Hae-Young Kim
New York Medical College

Brian Claggett
John Spertus
John F Heitner

See next page for additional authors

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Lewis, E., Kim, H., Claggett, B., Spertus, J., Heitner, J., Assmann, S., Kenwood, C., Solomon, S., Desai, A.,
Fang, J., McKinlay, S., Pitt, B., & Pfeffer, M. (2016). Impact of Spironolactone on Longitudinal Changes in
Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an
Aldosterone Antagonist Trial. Circulation: Heart Failure, 9 (3), 001937. https://doi.org/10.1161/
CIRCHEARTFAILURE.114.001937

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information,
please contact touro.scholar@touro.edu.

Authors
Eldrin Lewis, Hae-Young Kim, Brian Claggett, John Spertus, John F Heitner, Susan F Assmann, Christopher
T Kenwood, Scott D Solomon, Akshay S Desai, James C Fang, Sonia A McKinlay, Bertram A Pitt, and Marc
A Pfeffer
Author(s) ORCID Identifier:
https://orcid.org/0000-0001-7916-6625

This article is available at Touro Scholar: https://touroscholar.touro.edu/nymc_fac_pubs/1571

Original Article
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Scott D. Solomon, MD; Akshay S. Desai, MD; James C. Fang, MD;
Sonia A. McKinlay, PhD; Bertram A. Pitt, MD; Marc A. Pfeffer, MD, PhD;
for the TOPCAT Investigators
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Background—Heart failure (HF) with preserved ejection fraction patients have equally impaired health-related quality of
life (HRQL) compared with those with HF with reduced ejection fraction, but limited studies have evaluated the impact
of therapies on changes in HRQL.
Methods and Results—Patients ≥50 years of age, with symptomatic HF and left ventricular ejection fraction ≥45%, were
enrolled in Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) and
randomized to spironolactone or placebo. Patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ),
which was the primary HRQL instrument, and EQ5D visual analog scale at baseline, 4 months, 12 months, and annually
thereafter. McMaster Overall Treatment Evaluation was assessed at 4 and 12 months to assess global change scores. Change
scores (+SD) were calculated to determine between-group differences, and multivariable repeated-measures models were
created to identify other factors associated with change scores. Paired KCCQ data were available for 91.7% of 3445
TOPCAT patients. By 4 months, the mean change in KCCQ was 7.7±16 and mean change in EQ5D visual analog scale was
4.7±16. Adjusted mean changes in KCCQ for the spironolactone group were significantly better than those for the placebo
group at 4-month (1.54 better; P=0.002), 12-month (1.35 better; P=0.02), and 36-month (1.86 better; P=0.02) visits.
No between-group differences in EQ5D visual analog scale change scores or McMaster Overall Treatment Evaluation
were noted. Older age, obesity, current smoking, New York Heart Association class III/IV, and comorbid illnesses were
associated with declines in KCCQ scores. Use of spironolactone was an independent predictor of improved KCCQ scores.
Conclusions—In symptomatic HF with preserved ejection fraction patients, use of spironolactone was associated with an
improvement in HF-specific HRQL. Several modifiable risk factors were associated with HRQL deterioration.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.  
(Circ Heart Fail. 2016;9:e001937. DOI: 10.1161/CIRCHEARTFAILURE.114.001937.)
Key Words: clinical trial

■

heart failure

■

predictors

H

alf of the entire heart failure (HF) population have
HF with preserved ejection fraction (HF-PEF), with
over-representation among elderly, women, and minority populations.1,2 Patients with HF-PEF have equally
impaired health status compared with those with HF with
reduced ejection fraction (HF-REF) because of similarly
impaired functional capacity, signs and symptoms of HF,
and depression.3,4 Health-related quality of life (HRQL)

■

preserved ejection fraction

■

quality of life

is a component of health status and will be used in this
article for simplicity. However, no therapy has been proven
to improve survival and hospitalizations in large clinical
trials of HF-PEF patients,5–7 and few trials have evaluated
the impact of treatments on HRQL in this understudied
population.8–10

See Clinical Perspective

Received November 15, 2014; accepted January 22, 2016.
From the Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (E.F.L., B.C., S.D.S., A.S.D., M.A.P.); New England Research
Institutes, Watertown, MA (H.-Y.K., S.F.A., C.T.K., S.A.M.); Mid America Heart Institute/UMKC, Kansas City, MO (J.S.); Division of Cardiology, New
York Methodist Hospital, Brooklyn (J.F.H.); University of Utah, Division of Cardiology, Salt Lake City (J.C.F.); and University of Michigan School of
Medicine, Ann Arbor (B.A.P.).
Guest Editor for this article was Douglas L. Mann, MD.
The Data Supplement is available at http://circheartfailure.ahajournals.org/lookup/suppl/doi:10.1161/CIRCHEARTFAILURE.114.001937/-/DC1.
Correspondence to Eldrin F. Lewis, MD, MPH, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail
eflewis@partners.org
© 2016 American Heart Association, Inc.
Circ Heart Fail is available at http://circheartfailure.ahajournals.org

DOI: 10.1161/CIRCHEARTFAILURE.114.001937

1

2   Lewis et al   Spironolactone and Quality of Life in HF
The Treatment of Preserved Cardiac Function Heart
Failure With an Aldosterone Antagonist (TOPCAT)6 was conducted in 6 countries and enrolled a large number of symptomatic HF-PEF patients to test whether spironolactone improved
outcomes compared with placebo. The trial demonstrated a
reduction in HF hospitalizations, but no improvement in the
primary combined end point of cardiovascular mortality, HF
hospitalizations, or aborted cardiac arrest. A key prespecified
secondary outcome measure was the impact of spironolactone
on changes in HRQL.11 The primary objective of this article
is to provide the detailed analysis of the effect of spironolactone on short- (4 and 12 months) and long-term (>12 months)
changes in HRQL. A secondary objective is to determine the
factors associated with changes in HRQL.

Methods
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The design, patient characteristics, and primary outcome for TOPCAT
have been previously published.6,11,12 Briefly, TOPCAT study was
a multicenter, international, randomized, double-blind, placebocontrolled trial of spironolactone versus placebo in subjects with
symptomatic HF-PEF enrolled in United States, Russia, Republic of
Georgia, Canada, Brazil, and Argentina. Participants were enrolled
from August 2006 until January 2012. The subjects enrolled in the
study were ≥50 years of age, with left ventricular ejection fraction
≥45% and either a hospitalization primarily for the treatment of HF
within the year before randomization (hospitalization stratum) or an
elevated natriuretic peptide level within 60 days before randomization (natriuretic peptide stratum). Key exclusion criteria included life
expectancy<3 years, uncontrolled hypertension, constrictive pericarditis, known infiltrative or hypertrophic cardiomyopathy, history of
serious or unprovoked hyperkalemia, and estimated glomerular filtration rate <30 mL/min per 1.73 m2. TOPCAT was conducted with the
approval of local institutional review boards.

Assessment of Quality of Life
Three self-administered questionnaires were used to assess different
aspects of HRQL: the Kansas City Cardiomyopathy Questionnaire
(KCCQ)13 for assessing HF-specific HRQL related to HF, the EQ5D
Visual analog scale (EQ5D-VAS)14 for assessing generic HRQL to
measure non–HF related perceptions, and the McMaster Overall
Treatment Evaluation (McMaster OTE) for assessing the individual
patient’s perception of overall changes in HRQL since the beginning
of therapy to help quantify change scores.15 The primary HRQL outcome measure is the KCCQ overall summary score with supportive
analyses of the other 2 instruments. The KCCQ is a HF-specific 23item self-administered questionnaire developed to evaluate HF patients’ HRQL, symptoms, and function. Domains include physical
limitation, symptoms (frequency, severity, and change over time),
quality of life, social limitations, and self-efficacy. Each response is
given an ordinal value, and scale scores are transformed into a 0 to
100 range, with higher scores indicating better HRQL. KCCQ has
been validated in HF populations, including in HF-PEF,16 and is responsive to important changes in health state.17,18 A clinically meaningful difference in KCCQ score is established as 5 points.18 The
EQ5D-VAS has 5 items for utility assessment and a single VAS for
generic HRQL.14 The 5-item utility portion of the EQ-5D was not
administered to minimize burden to the subjects because cost-effectiveness analysis were not required. Only the single VAS component
was used, which is a vertical scale from 0 to 100, with 0 representing the worst possible HRQL and 100 representing the best possible
HRQL. The EQ5D-VAS has been used in multiple populations, including HF,19,20 and a clinically meaningful difference in EQ5D-VAS
score is established as 5 points.21 The McMaster Overall Treatment
Evaluation15 is a self-administered 3-item instrument that measures
the patient’s perception of changes in their HRQL since start of
therapy. The first question asks if there has been a change in their
health since treatment began. The subject responds with a check in 1

of 3 boxes: better, no change, or worse. If either better or worse was
checked, then the second question asks the subject to rate how much
better (worse) their condition has changed ranging from a very great
deal better (worse) to almost the same, hardly better (worse) at all.
The scores obtained on a Likert scale ranged across 15 points from +7
to −7, with a score of 0 for subjects who stated no change on question
1. Question 3 asked “how important is this change (better/worse) to
you?” on a 7-point scale. These 3 instruments collectively provide an
overall assessment of the impact of therapy on patients’ HRQL.
The KCCQ and EQ5D-VAS (with appropriate validated translations in all languages) were given to all participants enrolled in the
study. The KCCQ and EQ5D-VAS were administered at baseline,
4 months, 12 months, and then annually until final study visit. The
McMaster OTE was administered at 4 months and 12 months only for
subjects in the United States, Canada, and Argentina to ensure valid
translations of this instrument.

Statistical Analysis
The prespecified primary HRQL outcome measure was the KCCQ
overall summary score. The outcomes were predefined as changes
in KCCQ and EQ5D-VAS, and change scores were computed from
baseline to each study visit occurring at months 4, 12, 24, 36, 48, and
60 with primary focus on the first 12 months with unadjusted change
scores created. For each outcome, a backward selection method was
used to select the baseline covariates, which were significantly associated with change in outcome at each time point to identify factors that influence the change scores in addition to randomization.
Randomized treatment group, randomization stratum, and the baseline value of the outcome measure were forced into all covariateadjusted models. Candidate variables were prespecified. Otherwise,
nonsignificant variables were not included in final model. Mean
changes at each time point were compared across the 2 randomized
treatment groups using analysis of covariance, adjusting for baseline
outcome value, stratum, and all baseline covariates significant for that
outcome at ≥1 visit. The impacts of therapy on changes in KCCQ
and EQ5D-VAS scores over time were examined using a repeatedmeasure analysis of covariance (using all follow-up time points). A
Bonferonni correction was applied to both analysis of covariance
models given multiple testing as a conservative estimate (P<0.0083
corrected). Time was treated as a categorical variable (months 4, 12,
24, 36, 48, and 60), and the interaction term of treatment and time
was tested to examine whether treatment group effect on change in
each outcome differed depending on the time point.
The repeated-measures models were also repeated separately
for subjects in each of the 2 regions (Americas and Eastern Europe)
given the significant differences in patient characteristics and clinical outcomes in the primary article.6 The impact of randomization
on change scores was calculated for patients who permanently
discontinued study drug and those who did not discontinue study
drug. The proportion of subjects in each treatment arm reporting
improvement, no change, or decline on the McMaster OTE was calculated. Statistical analyses were performed at the TOPCAT Data
Coordinating Center at New England Research Institutes (Watertown,
MA) with SAS Version 9.3 statistical software (SAS Institute) and
R Version 3.0.2 software (R Foundation for Statistical Computing,
http://www.r-project.org/) and verified at the Brigham and Women’s
Hospital. A P<0.05 was considered statistically significant.

Results
The distributions of KCCQ and EQ5D-VAS scores at each
follow-up visit are presented in Table 1. Of the 3445 patients
enrolled in TOPCAT, paired baseline and follow-up KCCQ
data were available for 3158 (91.7%) at 4 months and
2902 (84.2%) at 12 months. Paired EQ5D-VAS data were
available for 3149 (91.4%) at 4 months and 2886 (83.8%)
at 12 months. At 24 months, ≈69% completed KCCQ and
EQ5D-VAS scores with decreasing responses for subsequent
months (Table 1). The mean KCCQ score was 54.8±21 at
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Table 1.

Means and Frequencies of KCCQ and EQ5D-VAS Scores at Each Visit
Baseline
(N=3400)
N

KCCQ score 3400
Change
in KCCQ
score

Month 4
(N=3190)

Mean±SD or
N(%)

N

Mean±SD or
N(%)

54.8±19.6

3176

N/A

3158

Month 12
(N=2951)
N

Mean±SD or
N(%)

62.8±19.6

2922

7.7±15.9

2902

Month 24
(N=2408)
N

Mean±SD or
N(%)

63.8±20.1

2379

64.7±19.6

8.2±18.0

2364

8.9±18.5

Month 36
(N=1792)
N

Mean±SD
or N(%)

Month 48
(N=1267)
N

1776 65.2±19.2 1258
1762

9.4±19.2 1250

Mean±SD
or N(%)

Month 60 (N=809)
N

Mean±SD
or N(%)

65.7±19.0 808 66.2±18.8
9.9±19.3 807 11.1±20.2

KCCQ
Categories
 0–25

219 (6.4%)

83 (2.6%)

93 (3.2%)

75 (3.2%)

52 (2.9%)

39 (3.1%)

23 (2.8%)

 26–50

1260 (37.1%)

787 (24.8%)

639 (21.9%)

471 (19.8%)

324 (18.2%)

211 (16.8%)

123 (15.2%)

 51–75

1281 (37.7%)

1416 (44.6%)

1282 (43.9%)

1065 (44.8%)

810 (45.6%)

572 (45.5%)

379 (46.9%)

 76–100

640 (18.8%)

768 (32.3%)

590 (33.2%)

436 (34.7%)

283 (35.0%)

EQ5D score 3395

60.3±17.3

3172

65.3±16.5

2912

65.9±16.5

2374

66.6±16.2

1773 67.4±15.6 1257

N/A

3149

4.7±16.2

2886

5.0±17.2

2355

5.7±17.9

Change
in EQ5D
score

890 (28.0%)

908 (31.1%)

1756

7.0±17.8 1247

67.7±15.7 805 68.4±15.7
7.8±17.9 803

8.6±18.1)

EQ5D-VAS
categories
 0–25

100 (2.9%)

51 (1.6%)

43 (1.5%)

35 (1.5%)

21 (1.2%)

19 (1.5%)

7 (0.9%)

 26–50

1134 (33.4%)

707 (22.3%)

650 (22.3%)

499 (21.0%)

336 (19.0%)

228 (18.1%)

145 (18.0%)

 51–75

1582 (46.6%)

1629 (51.4%)

1452 (49.9%)

1154 (48.6%)

866 (48.8%)

604 (48.1%)

361 (44.8%)

 76–100

579 (17.1%)

785 (24.7%)

767 (26.3%)

686 (28.9%)

550 (31.0%)

406 (32.3%)

292 (36.3%)

COPD indicates chronic obstructive lung disease; CV, cardiovascular; EQ5D-VAS, EQ5D visual analog scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; and
NYHA, New York Heart Association.
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baseline and increased to 62.8±20 by 4 months and 63.8±20
by 12 months. The mean EQ5D-VAS score was 60.3±17 at
baseline and increased to 65.3±16 by 4 months and 65.9±17
by 12 months.

Quality of Life Outcomes
The unadjusted and adjusted mean change (±standard error)
in KCCQ scores from baseline at each visit are presented by
treatment group in Figure 1A and 1B. The unadjusted mean
change improved in both spironolactone and placebo groups
during follow-up. The adjusted mean change in KCCQ was
significantly higher in the spironolactone group than in the
placebo group at month 4 (P=0.002) and month 12 (P=0.02),
with less consistent differences beyond 12 months. Randomization to spironolactone was also associated with improved
KCCQ clinical scores and KCCQ symptom scores at 4
months compared with placebo; however, these differences
did not persist beyond 4 months (Figure I in the Data Supplement). There were no significant treatment group differences
in the other KCCQ domains (social interference, physical
scores, quality of life) during follow-up. The unadjusted and
adjusted mean changes (±standard error) in EQ5D-VAS are
presented in Figure 2. There was no significant difference
in mean change in EQ5D-VAS between spironolactone and
placebo groups at any visit in either the unadjusted or the
adjusted analyses. There were no significant differences in the
McMaster OTE perception of change scores at 4 months and
12 months in patients randomized to spironolactone versus
placebo (Figure 3).

When evaluating patients on study drug, there were significant improvements in KCCQ for spironolactone versus placebo at 4 and 12 months with persistence through 48 months
(Figure IIA in the Data Supplement). No differences were
seen in EQ5D-VAS change scores between the groups (Figure
IIB in the Data Supplement).

Predictors of Longitudinal Changes in KCCQ and
EQ5D-VAS
In the multivariable repeated-measures model, randomization
to spironolactone was associated with a 1.36 point additional
increase in KCCQ scores compared with the change for subjects randomized to placebo, adjusting for all other variables
(Table 2). Additional predictors of improvements in KCCQ
scores include hospitalization stratum, living in the Americas
(as opposed to Russia/Georgia), and taking other cardiovascular medications. The percentage of meals eaten at home was
also associated with changes in KCCQ but the effects were
not linear. Predictors of declines in KCCQ scores include
New York Heart Association (NYHA) Class III/IV functional
class, older age, higher baseline KCCQ score, obesity, current smoking, use of a hypoglycemic medicine, history of
chronic obstructive lung disease, bone fractures, hypertension, and thyroid disease. There was a general upward trend
in KCCQ changes over time, although the overall test for
time was not statistically significant (P=0.055). The difference in mean EQ5D-VAS change between treatment groups
was 0.467 points, which was not statistically significant
(P=0.223), and the difference in change in EQ5D-VAS over
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Figure 1. Unadjusted (A) and adjusted (B) mean (SE) of change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline at
each visit by treatment group.
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time was significant (P<0.001), indicating that the average
change in EQ5D-VAS was increasing over time (Table 3).
Several predictive variables for KCCQ scores were consistent
predictors for the EQ5D-VAS change scores, including living in the Americas with improved scores and obesity, chronic
obstructive lung disease, bone fracture, thyroid disease,
NYHA Class III/IV, and use of a hypoglycemic agent with a
decline in EQ5D-VAS. Compared with non-Hispanic White
patients, Black and Hispanic patients noted improvements in

EQ5D-VAS over time, but not in KCCQ scores. The presence
of chronic kidney disease and atrial fibrillation were associated with declines in EQ5D-VAS, but not in KCCQ scores.

Regional Differences in Quality of Life Responses
Given the regional differences between patient characteristics and outcomes between those randomized in the Americas
versus Russia/Georgia, all key analyses were repeated in both
regions separately. Patients in the Americas (Table I in the

Figure 2. Unadjusted (A) and adjusted (B) mean (SE) of change in EQ5D visual analog scale (EQ5D-VAS) from baseline at each visit by
treatment group.
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Figure 3. Impact of spironolactone vs placebo on
patient’s perception of change using McMaster Overall Treatment Evaluation.
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Data Supplement) started with a better overall HRQL and had
a smaller improvement over time than patients in Russia/Georgia (Table II in the Data Supplement). Patients randomized
to spironolactone in the Americas noted a 2.079±0.74 greater
improvement in KCCQ compared with placebo patients
(P=0.005). In contrast, subjects randomized to spironolactone
in Russia/Georgia noted a 0.654±0.50 greater improvement in
KCCQ compared to placebo patients (P=0.192). However, the
interaction term of region and treatment group was not significant (P for interaction=0.130). Additional regional similarities and differences are detailed in Figure IIIA and IIIB
in the Data Supplement. The multivariable models did not
change dramatically for either KCCQ (Tables III and IV in
the Data Supplement) or EQ5D-VAS (Tables V and VI in the
Data Supplement).

Discussion
The management goals of HF-PEF patients continue to
improve survival, reduce morbidity and hospitalizations,
attenuate disease progression, and improve HRQL and exercise capacity. Patient’s preferences for the priority of these
goals are highly individualized.22 Despite the importance of
HRQL in HF-PEF, limited data exist on the impact of therapies on this important patient-reported outcome.23,24 The
primary HRQL analysis of TOPCAT demonstrated that spironolactone use was associated with a statistically significant
improvement in HRQL using the HF-specific KCCQ driven
by improvements in symptoms and clinical scores domains.
However, there was not an improvement in generic HRQL
based on EQ5D-VAS or in the McMaster OTE, suggesting
that non–HF related HRQL was not influenced. In a multivariable model that adjusted for baseline HRQL and factors
associated with HRQL, use of spironolactone remained statistically associated with improvements in HRQL using repeated
measures extending to 60 months.
Improving HRQL in patients with medical therapy has
historically been difficult given the various factors associated with change scores, insensitivities of the instruments to
measure small (but important) differences, and lack of complete data during longer follow-up periods in part because of

competing risks of death. Use of spironolactone was associated
with a short-term and long-term difference in KCCQ scores.
The generic HRQL (measured by EQ5D-VAS) improved in
both groups without a between-treatment difference. As in
other publications of TOPCAT with disparate outcomes in
the Americas and Russia/Georgia,6,25 there were regional differences in HRQL responses with significant improvements
in the Americas. After adjusting for baseline characteristics,
randomized treatment group, and baseline HRQL values,
mean changes in KCCQ and EQ5D were significantly better
for patients from the Americas than for those from Russia/
Georgia. However, the patient characteristics and other predictors of change scores were similar in the 2 regions.
Several studies have evaluated therapies on HRQL in
HF-PEF. The Aldosterone Receptor Blockade in Diastolic
Heart Failure (ALDO-DHF) study randomized 422 patients
with HF-PEF to spironolactone or placebo, and there was no
difference in Minnesota Living with Heart Failure (MLHF)
scores by 12 months.8 The Irbesartan in Heart Failure with
Preserved Ejection Fraction study (I-PRESERVE) demonstrated no impact of irbesartan on changes in MLHF scores
compared with placebo, although both groups noted clinically
meaningful changes.5 The Phosphodiesterase-5 Inhibition
to Improve Clinical Status and Exercise Capacity in Heart
Failure with Preserved Ejection Fraction (RELAX) trial demonstrated no differences in change of HRQL using the MLHF
questionnaire with median improvements of 8 points in both
sildenafil and placebo groups.9 Patients receiving candesartan in CHARM-Preserved noted an improvement in overall
perception of change in their HRQL compared with placebo,
but impact on MLHF scores has not been reported.26 There is
more experience with KCCQ in HF-REF populations. Systolic
Heart Failure Treatment With the If Inhibitor Ivabradine Trial
(SHIFT) assessed HRQL in HF-REF and demonstrated a
similar magnitude of improvement in KCCQ scores over 12
months with a 2.4 point between-group difference between
ivabradine and placebo.27 Multicenter Automatic Defibrillator
Implantation Trial With Cardiac Resynchronization Therapy
(MADIT-CRT) enrolled 1699 patients with NYHA Class I/
II HF and demonstrated improvement in KCCQ of 1.3 points
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Table 2.

Repeated Measures Model for Changes in KCCQ

Table 2.

Continued

Changes in KCCQ
Model Covariates
Randomization to spironolactone
(vs placebo)

Estimates (SE)
1.36 (0.44)

Visit month

P Value*
0.002
0.055†

 12 (vs 4)

0.53 (0.28)

0.057

 24 (vs 4)

0.79 (0.33)

0.017

 36 (vs 4)

0.79 (0.38)

0.038

 48 (vs 4)

1.18 (0.43)

0.006

 60 (vs 4)

1.46 (0.51)

0.004

Baseline KCCQ score
(per 1 point increase)

−0.42 (0.01)

<0.001

Hospitalization stratum

1.44 (0.55)

0.009

Americas‡ (vs Russia/Georgia)

2.14 (0.78)

0.006

−0.08 (0.03)

0.002

Age, y
Race/ethnicity
 Black, non-Hispanic (vs White,
non-Hispanic)
 Hispanic (vs White, non-Hispanic)

0.640†
1.00 (0.98)

0.308

0.30 (0.91)

0.742

 Other/missing (vs White, non-Hispanic)

−1.37 (1.94)

0.481

Obesity

−1.73 (0.48)

<0.001

Smoking Status

0.022†
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 Current (vs never)

−1.82 (0.79)

0.022

 Former (vs never)

0.44 (0.51)

0.390

Atrial fibrillation

−1.07 (0.61)

0.077

Angina pectoris

−1.17 (0.78)

0.134

Asthma

−1.59 (0.96)

0.100

Coronary artery disease

−0.71 (0.84)

0.401

0.13 (0.60)

0.832

COPD

−2.33 (0.73)

0.002

Bone fracture

−1.83 (0.73)

0.012

Hypertension

−2.17 (0.81)

0.007

Pacemaker

−0.77 (0.90)

0.394

Stroke

−1.24 (0.85)

0.144

Thyroid disease

−1.40 (0.63)

0.025

0.57 (0.46)

0.219

Aspirin

−0.49 (0.52)

0.349

Statins

−0.53 (0.50)

0.291

Myocardial infarction

Calcium-channel blocker

Warfarin

0.05 (0.71)

0.948

−1.56 (0.56)

0.005

Other CV medication§

1.20 (0.49)

0.014

Cooking salt score

0.00 (0.07)

0.996

Hypoglycemic agent

Meals at home, %

0.012†

 Almost all (vs None)

1.06 (1.08)

0.326

 75% (vs None)

1.02 (1.19)

0.391

 50% (vs None)

0.00 (1.32)

0.998

 25% (vs None)

5.01 (1.62)

Living situation
 Currently living with spouse/
sig other (vs living alone)

0.002
0.092†

1.05 (0.57)

0.066
(Continued )

Changes in KCCQ
Model Covariates

Estimates (SE)

P Value*

 Currently living with someone other than
spouse (vs living alone)

−0.16 (0.87)

0.856

NYHA functional class III/IV (vs I/II)

−2.13 (0.51)

<0.001

The baseline KCCQ score was 54.8. COPD indicates chronic obstructive lung
disease; CV, cardiovascular; KCCQ, Kansas City Cardiomyopathy Questionnaire;
and NYHA, New York Heart Association.
*All P values provided are from t tests with exception of those denoted with
† from Type 3 F-Test. Models contain all covariates that were statistically
significant across the 6 time points.
‡Americas represent subjects enrolled in United States, Canada, Brazil, or
Argentina.
§CV medications other than aspirin, calcium-channel blocker, hypoglycemic
agent, long-acting nitrate, statin, warfarin, diuretic, angiotensin-converting
enzyme inhibitor (ACE-I), angiotensin receptor blocker (ARB), beta-blocker.

better than defibrillator alone and 2 points better in cohort
with left bundle branch block.28 The Placement of Aortic
Transcatheter Valve (PARTNERS) trial evaluated transcutaneous aortic valve replacement versus surgical aortic valve
replacement and demonstrated significant improvements
in KCCQ at 1 month with a 5.5 point difference, but there
were no differences at 6 or 12 months.29 The addition of surgical ventricular restoration to bypass surgery did not result
in significant difference between KCCQ change scores in
comparison to bypass alone in The Surgical Treatment for
Ischemic Heart Failure (STICH).30 Finally, the magnitude of
change and between-group differences in TOPCAT was similar to the magnitude seen with cardiac rehabilitation in the
Heart failure: a Controlled Trial Investigating Outcomes of
Exercise Training (HF-ACTION) trial (5.2 versus 3.3 point
change score in comparison with usual care).31 Thus, the
noted improvements in HRQL with spironolactone in HF-PEF
deserve closer evaluation.
Understanding factors that influence future HRQL can be
important for medical decision making about therapies and
goals of care, especially as some patients will prefer HRQL as
the more important outcome.32–34 We identified several factors
that are associated with declining KCCQ scores during follow-up, including older age, obesity, active smoking, need for
hypoglycemic agents, NYHA Class III or IV functional capacity, and comorbid illnesses beyond HF. Some of these same
factors influenced baseline HRQL as well.35 Interestingly,
despite female sex influencing baseline HRQL,35 this did not
influence longitudinal change in HRQL and did not make it
into the final model. Older age and diabetes mellitus are 2 factors that influenced future declines in HRQL in HF-REF.36 A
study enrolling 111 HF-REF and HF-PEF patients referred to
cardiac rehabilitation demonstrated that higher BMI and worse
NYHA class at baseline were associated with worse HRQL
over a mean of 2.8 years.37 Smokers had a nonsignificant trend
toward worse HRQL. The presence of chronic obstructive lung
disease, thyroid disease, and hypertension may increase anxiety or directly impact symptom burdens with some overlap
with HF symptoms and could lead to decrements in HRQL.
The presence of some of these comorbid illnesses may impact
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Table 3.

Repeated Measures Model for Changes in EQ5D-VAS
Changes in EQ5D-VAS

Model Covariates

Estimates (SE)

Randomization to spironolactone (vs placebo)

0.47 (0.38)

Visit month

P Value*
0.223
<0.001†

 12 (vs 4)

0.35 (0.27)

 24 (vs 4)

0.78 (0.33)

0.018

 36 (vs 4)

1.51 (0.36)

<0.001

 48 (vs 4)

2.04 (0.42)

<0.001

 60 (vs 4)

2.35 (0.48)

<0.001

Baseline EQ5D-VAS score (per 1 point increase)

−0.59 (0.01)

<0.001

Hospitalization stratum

−0.03 (0.48)

0.956

1.69 (0.67)

0.012

Americas‡ vs Russia/Georgia
Age, y

−0.05 (0.02)

Race/ethnicity

0.200

0.051
<0.001†

 Black, non-Hispanic (vs White, non-Hispanic)

2.61 (0.86)

0.003

 Hispanic (vs White, non-Hispanic)

3.37 (0.80)

<0.001

 Other/missing (vs White, non-Hispanic)

−0.32 (1.71)

0.851

Obesity

−1.52 (0.42)

<0.001

Atrial fibrillation

−1.06 (0.53)

0.043

Angina pectoris

−0.63 (0.71)

0.371

Coronary artery bypass grafting

−0.06 (0.66)

0.928

Coronary artery disease

−0.80 (0.80)

0.316

Chronic kidney disease

−1.18 (0.42)

0.005

COPD

−1.76 (0.63)

0.005

1.93 (0.87)

0.026

Bone fracture

−2.05 (0.64)

0.001

Hypertension

−1.22 (0.70)

0.082

Implantable cardioverter defibrillator

0.64 (1.73)

0.711

Myocardial infarction

0.35 (0.52)

0.503

Stroke

−0.81 (0.74)

0.276

Thyroid disease

−1.29 (0.55)

0.018

PCI

−0.84 (0.64)

0.190

Hypoglycemic agent

−3.15 (0.92)

<0.001

Warfarin

−0.11 (0.62)

0.855

Long-acting nitrate

−1.36 (0.57)

0.017

0.45 (0.45)

0.324

Diabetes mellitus
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Aspirin
Other CV medication§
Cooking salt score

−0.38 (0.43)

0.372

0.21 (0.06)

<0.001

Meals at home, %

0.006†

 Almost all (vs none)

0.07 (0.95)

0.940

 75% (vs none)

1.23 (1.05)

0.242

 50% (vs none)

−1.48 (1.16)

0.203

 25% (vs none)

2.39 (1.43)

0.094

−2.69 (0.44)

<0.001

NYHA functional class III/IV (vs I/II)

The baseline EQ5D-VAS score was 60.3. COPD indicates chronic obstructive
lung disease; CV, cardiovascular; KCCQ, Kansas City Cardiomyopathy
Questionnaire; NYHA, New York Heart Association; PCI, percutaneous coronary
intervention.
*All P values provided are from t tests with exception of those denoted with
† from Type 3 F-Test. Models contain all covariates that were statistically
significant across the 6 time points.
‡Americas represent subjects enrolled in United States, Canada, Brazil, or
Argentina.
§CV medications other than aspirin, calcium-channel blocker, hypoglycemic
agent, long-acting nitrate, statin, warfarin, diuretic, angiotensin converting
enzyme inhibitor (ACE-I), angiotensin receptor blocker (ARB), beta blocker.

the degree to which a HF-specific intervention can improve
a patient’s HRQL, and this complex interaction should be
further elucidated in future research. Interim cardiovascular
events were not included in the model, and this may provide
a link between excess comorbid illnesses and more severe HF
with decrements in HRQL.20 In contrast, few factors improved
KCCQ scores longitudinally. Randomization to spironolactone
independently improved KCCQ even after adjusting for all
important factors. Nevertheless, given the equal impairment in
HRQL between HF-PEF and HF-REF patients,3 confirmation
of the factors that influence declines in HRQL is important,
especially because some of these factors are modifiable.
There are several limitations to this analysis. First, there
was a dramatic decline in the completion of the HRQL instruments beyond 12- and 24-month visits, which creates a healthy
cohort effect that may have caused the overall mean HRQL
scores to improve over time. Moreover, nonfatal events may
influence these HRQL perceptions. Focus on change scores
should be within a short time frame as the primary efficacy end
point for HRQL (eg, 6–8 months) to avoid competing risks of
death, attrition, and comorbid illnesses. The large sample size
with 3 distinct measures of HRQL may identify statistically
significant differences that may not be perceivable by patients.
However, the a priori determination of KCCQ as the primary
HRQL measure reduces this concern. Populations in clinical
trials tend to be healthier than the community-based cohorts,
and HRQL responses to spironolactone may be different in
patients who were not eligible for enrollment in TOPCAT.
Finally, close follow-up and frequent visits may have influenced HRQL beyond the therapy, which may be the reason for
over 50% of subjects having a clinically meaningful change
score in the KCCQ in the placebo arm. Nevertheless, this is
one of the largest studies in HF-PEF assessing HRQL.
In conclusion, stable, symptomatic patients with
HF-PEF who receive spironolactone note an improvement
in HF-specific HRQL compared with patients receiving placebo by 4 months, and this difference is seen ≤36 months.
The beneficial effects are independent of multiple factors that
influence patient change scores. Given the relatively small
magnitude of change scores, further research is required to
better delineate the potential role of this therapy to improve
HRQL, an important target of novel interventions in this
undertreated population.
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CLINICAL PERSPECTIVE
This study reports the primary quality of life longitudinal outcomes for the Treatment of Preserved Cardiac Function Heart
Failure With an Aldosterone Antagonist Trial (TOPCAT), one of the largest trials conducted on patients with heart failure
with preserved ejection fraction. Given the equally impaired quality of life in this population compared with heart failure
with reduced ejection fraction, strategies to improve these outcomes are paramount. The relative complete ascertainment
of quality of life data allowed for rigorous assessments of longitudinal impact of therapy. Patients who were randomized
to spironolactone noted improved quality of life using the Kansas City Cardiomyopathy Questionnaire in comparison to
patients receiving placebo. These differences were noted by 4 months and persisted to 36 months. No differences were seen
with generic measures of quality of life (EQ-5D and McMaster Overall Treatment Evaluation). Independent predictors of
declines in quality of life included older age, obesity, current smoking, comorbid illnesses, and advanced New York Heart
Association class III/IV. Some of these reversible factors may be novel targets for improving quality of life in this patient
population. Moreover, clinicians may consider more careful evaluation of their patients’ quality of life when they have these
high-risk features because more intensive and focused management may attenuate this progressive decline and may help in
shared decision making about goals of care. Overall, these results suggest a modest, but statistically significant, improvement
in quality of life with the use of spironolactone in heart failure with preserved ejection fraction patients.

